THU, 08 OCT 2026|
[BRAND]
LATEST
01Rahm leaving LIV Golf in blow to future of bankrupt league02OBJ signs with Vikings on practice squad after release by Giants03Watch — Where’s the ANC? Inside the party’s quietest election campaign yet04Syria weighs military aid for Saudi Arabia amid Yemen war, sources say05Children killed while they slept as Russian missile kills 19 in block of flats06T20 ties have softened on-field rivalries, says Harmer07A 194-year-old tortoise, world's oldest land animal, may hold clues to longer life08Fed officials see another hike coming, but no sign as to when, minutes show
Feed/Economy · Finance
Economy · Finance

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

CNBC · World
Published 3 Oct 2026, 1:20 am·5 d ago·1 min read
Listen to this story
Read aloud by your device

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Read the full story at CNBC · World
cnbc.com
Open ↗

Related

Economy · Finance

Fed officials see another hike coming, but no sign as to when, minutes show

6 h ago·CNBC · World·1 min read
Economy · Finance

Anthropic launches third Claude 5.5 model, expanding AI lineup before planned IPO

6 h ago·CNA·1 min read
Economy · Finance

10-year Treasury yield ease from 24-year high after solid bond auction eases demand fears

6 h ago·CNBC · World·1 min read
Economy · Finance

What Singapore really thinks of Australian solar power export plan

6 h ago·ABC News (AU)·1 min read
Economy · Finance

France to release 10m barrels of diesel from stocks

6 h ago·Middle East Eye·1 min read